Bin Peng, Liying Cui. Anticoagulation and Bleeding: Balancing the Benefit and the Riskin Clinical Decision-making[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 97-102. doi: 10.3969/j.issn.1674-9081.2018.02.001
Citation: Bin Peng, Liying Cui. Anticoagulation and Bleeding: Balancing the Benefit and the Riskin Clinical Decision-making[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 97-102. doi: 10.3969/j.issn.1674-9081.2018.02.001

Anticoagulation and Bleeding: Balancing the Benefit and the Riskin Clinical Decision-making

doi: 10.3969/j.issn.1674-9081.2018.02.001
More Information
  • Corresponding author: CUI Li-ying   Tel: 010-69156373, E-mail: pumchcuily@sina.com
  • Received Date: 2017-12-27
  • Publish Date: 2018-03-30
  • Anticoagulation therapy is highly effective in preventing thromboembolism in patients with atrial fibrillation, deep vein thrombosis, or genetic predisposition, etc. Despite this advantage, however, anticoagu-lation results in an elevated risk of bleeding that may sometimes be life-threatening. There is excess concern in patients and physicians about the risk of bleeding from anticoagulation, which leads to the use of anticoagulation reportedly much less than expected. It is crucial to assess the bleeding risk and balance the benefit and the risk in order to plan a proper therapeutic regimen. An optimal decision on the therapy is based on a good balance between anticoagulation and bleeding according to the patient condition, the choice of an appropriate evaluation scale, a comprehensive assessment of coagulation, the right selection of medicine and dosage, and the enforcement of the management of anticoagulation therapy.
  • loading
  • [1] Vinereanu D, Lopes RD, Bahit MC, et al. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial[J]. Lancet, 2017, 390:1737-1746. doi:  10.1016/S0140-6736(17)32165-7
    [2] Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review[J]. JAMA, 2015, 313:1950-1962. doi:  10.1001/jama.2015.4369
    [3] Eckman MH, Singer DE, Rosand J, et al. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation[J]. Circ Cardiovasc Qual Outcomes, 2011, 4:14-21. doi:  10.1161/CIRCOUTCOMES.110.958108
    [4] 中华医学会心血管病学分会, 中国老年学学会心脑血管病专业委员会, 中国生物医学工程学心律分会, 等.心房颤动抗凝治疗中国专家共识[J].中华内科杂志, 2012, 51:916-921. doi:  10.3760/cma.j.issn.0578-1426.2012.11.026
    [5] Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas[J]. Stroke, 2005, 36:1588-1593. doi:  10.1161/01.STR.0000170642.39876.f2
    [6] Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation[J]. Stroke, 2014, 45:1304-1312. doi:  10.1161/STROKEAHA.113.004506
    [7] Steiner T, Weitz JI, Veltkamp R. Anticoagulant-associated intracranial hemorrhage in the era of reversal agents[J]. Stroke, 2017, 48:1432-1437. doi:  10.1161/STROKEAHA.116.013343
    [8] Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction[J]. N Engl J Med, 2002, 347:969-974. doi:  10.1056/NEJMoa020496
    [9] Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: metaanalysis with estimates of risk and benefit[J]. Ann Intern Med, 2005, 143:241-250. doi:  10.7326/0003-4819-143-4-200508160-00005
    [10] Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data[J]. Lancet, 2009, 374:1967-1974. doi:  10.1016/S0140-6736(09)61751-7
    [11] Gutermann IK, Niggemeier V, Zimmerli LU, et al. Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice[J]. Medicine, 2015, 94:e377. doi:  10.1097/MD.0000000000000377
    [12] Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey[J]. Chest, 2010, 138:1093-1100. doi:  10.1378/chest.10-0134
    [13] Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation:the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score[J].JACC, 2011, 57:173-180. doi:  10.1016/j.jacc.2010.09.024
    [14] Hart RG, Pearee LA, Aguilar MI.Meta analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J].Ann Intern Med, 2007, 146:857, 867. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=17577005
    [15] Ferro JM, Bousser MG, Canhao P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis—endorsed by the European Academy of Neurology[J]. Eur J Neurol, 2017, 24:1203-1213. doi:  10.1111/ene.13381
    [16] 中华医学会神经病学分会.中国颅内静脉系统血栓形成诊断和治疗指南2015[J].中华神经科杂志, 2015, 48:819-829. doi:  10.3760/cma.j.issn.1006-7876.2015.10.002
    [17] Kernan WN, Ovbiagele B, Black HR, et al. Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American stroke association[J]. Stroke, 2014, 45:2160-2236. doi:  10.1161/STR.0000000000000024
    [18] 中华医学会神经病学分会.中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014[J].中华神经科杂志, 2015, 48:246-257. doi:  10.3760/cma.j.issn.1006-7876.2015.04.002
    [19] Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease chest guideline and expert panel report[J]. Chest, 2016, 149:315-352. doi:  10.1016/j.chest.2015.11.026
    [20] Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation[J]. J Arrhythm, 2017, 33:345-367. doi:  10.1016/j.joa.2017.05.004
    [21] Björck F, Renlund H, Lip GH, et al. Outcomes in a warfarin-treated population with atrial fibrillation[J]. JAMA Cardiol, 2016, 1: 172-180. doi:  10.1001/jamacardio.2016.0199
    [22] Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score[J]. Chest, 2013, 144: 1555-1563. doi:  10.1378/chest.13-0054
    [23] Freedman B, Potpara TS, Lip GYH. Stroke prevention in arterial fibrillation[J]. Lancet, 2016, 388:806-817. doi:  10.1016/S0140-6736(16)31257-0
    [24] Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation[J]. J Arrhythm, 2017, 33:345-367. doi:  10.1016/j.joa.2017.05.004
    [25] 中华医学会神经病学分会.中国急性缺血性卒中诊治指南2014[J].中华神经科杂志, 2015, 48:246-257. doi:  10.3760/cma.j.issn.1006-7876.2015.04.002
    [26] 中华医学会心血管病学会.华法林抗凝治疗的中国专家共识[J].中华内科杂志, 2013, 52:76-82. doi:  10.3760/cma.j.issn.0578-1426.2013.01.027
    [27] Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran the RE-LY trial[J]. Stroke, 2012, 43:1511-1517. doi:  10.1161/STROKEAHA.112.650614
    [28] Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascualr disease: a scientific statement from the American Heart Association [J]. Circulation, 2016, 134:e468-e495. doi:  10.1161/CIR.0000000000000456
    [29] Tincani E, Mazzali F, Morini L. Hypoalbuminemia as a risk factor for over-anticoagulation[J]. The Am J Med, 2002, 112:247-248. doi:  10.1016/S0002-9343(01)00957-3
    [30] Pernod G, Albaladejo P, Godier A, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)-March 2013[J]. Arch Cardiovasc Dis, 2013, 106:382-393. doi:  10.1016/j.acvd.2013.04.009
    [31] Peng B, Ni J, Anderson CS, et al. Implementation of a structured guideline-based program for the secondary prevention of ischemic stroke in china[J]. Stroke, 2014, 45:515-519. doi:  10.1161/STROKEAHA.113.001424
    [32] Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for diabigatran reversal-full cohort analysis[J]. N Engl J Med, 2017, 377:431-441. doi:  10.1056/NEJMoa1707278
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (307) PDF downloads(542) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return